Strategic partners in prosperity

Strategic partners in prosperity
The pharmaceutical contract services industry is faced with a decade of opportunity. While industry analysts recount the change in outsourcing strategies post the 2008 credit crunch in the first article, Waiting for the bounce back, the following two write ups, All ‘CRAM’ med up! and Playing BIG with CROs present a cross section of views from leading players themselves

Waiting for the bounce back
As global pharma continues to re-size, Indian CMOs and CROs are revamping their business models and moving to the next level, finds Viveka Roychowdhury

All ‘CRAM’ med up!
With an increase in the number of off-patent drugs available, the competition, both domestic and MNCs, are tapping custom manufacturing outsourcing in a big way. Usha Sharma provides an industry insight

Playing BIG with CROs
Slowly and steadily, the growing Indian CRO industry is expected to show positive growth in the coming future as well. Sachin Jagdale analyses the possible trends and challenges that the Indian CRO industry has to sail through

Daiichi Sankyo & Ranbaxy to integrate new drug R&D system
Daiichi Sankyo Company Ltd and Ranbaxy Laboratories Ltd recently announced that Ranbaxy’s New Drug Discovery Research (NDDR) has been transferred to Daiichi Sankyo India Pharma Pvt Ltd as part of the strategy to strengthen the global research and development (R&D) structure of the Daiichi Sankyo Group

‘Innovative and flexible global delivery model in ‘SYNC’ with industry needs’
Siro Clinpharm’s SYNC is all set to revolutionise the methods of clinical data management. Dr Nimita Limaye, Vice President, Clinical Data Management and Medical Writing, Siro Clinpharm, reveals more to Sachin Jagdale

Indoco consolidates its base in Francophone Africa and Latin America
Indoco Remedies (Indoco) consolidated its base in Francophone Africa and Latin America by establishing its presence in Ivory Coast and Senegal, with a focus on both trade and tender business

Alembic board approves de merger of pharma business
Alembic recently announced at its board meeting a re-organisation plan, which includes the de – merger of its core pharma business into a 100 percent subsidiary company called Alembic Pharma Ltd (APL) and reorganisation of its Vadodara Undertaking

Venus Remedies enters Australasian region
Venus Remedies recently marked its presence in the Australasia region by receiving a patent from Commissioner of Patents, Trademarks and Design, Intellectual Property office of New Zealand for its antibiotic Potentox, a fixed dose combination (FDC) of cefepime and amikacin

Frost & Sullivan workshop on Future Supply Chain Strategies
Keeping in perspective the challenges faced by the Logistics Service Providers (LSP’s) and End Users, Frost & Sullivan’s Transportation and Logistics Practice is organising an exclusive strategy workshop ‘Future Supply Chain Strategies’ from 14-16th July 2010, at The Golden Palms Hotel & Spa, Bengaluru, India

Event Brief

First NextGen conference concludes successfully
With patent expiration, originator companies out-license their products to their generic arms to stop price erosion by 40-60 percent